Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

The U.S. Food and Drug Administration (FDA) said it had completed its inspection of a U.S. plant that makes Johnson & Johnson's COVID-19 vaccine and asked for remediation of issues including peeling paint and loose debris at the site.

U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine

A Baltimore factory that botched the production of 15 million doses of the Johnson & Johnson COVID-19 vaccine has been cited for unsanitary conditions by the US Food and Drug Association. In a report on the factory for Emergent BioSolutions published by the FDA on Wednesday, officials said the facility had peeling paint and "brown residue" on the walls.

The FDA cited the vaccine plant that ruined millions of Johnson & Johnson doses for unsanitary conditions, finding "brown residue" on the walls and peeling paint

A congressional panel has launched an investigation into whether Emergent BioSolutions Inc (NYSE: EBS) was improperly awarded a $628 million federal contract to make COVID-19 vaccines based on its favorable relationship with a key Trump Administration official, despite officials knowing it has a history of quality control issues. Representatives Carolyn Maloney (D-N.Y.

House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify

NEW YORK--(BUSINESS WIRE)-- #EmergentBioSolutions--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of investors that purchased Emergent BioSolutions, Inc. (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsui

EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm

Congressional investigators have requested top executives from Emergent BioSolutions to testify before the Select Subcommittee.

Congressional investigation launched into Emergent BioSolutions' federal vaccine contracts

Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.

Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine manufactured at its Baltimore site. Then, the FDA seized the reins of the facility and passed them on to JNJ.

Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility

The Food and Drug Administration has asked Emergent BioSolutions to temporarily stop producing materials for Covid-19 vaccines while U.S. regulators investigate its plant in Baltimore responsible for ruining millions of Johnson & Johnson shots, Emergent said in a regulatory filing Monday.

FDA asks Emergent plant to pause manufacturing while it investigates botched Covid vaccines

Drug contract company Emergent BioSolutions Inc. said Monday it has made an agreement with the U.S. Food and Drug Administration not to manufacture any new material at its Bayview facility in Baltimore. The FDA started an inspection of the plant last week, after Johnson & Johnson found Emergent workers had confused ingredients for its COVID-19 vaccine with ones used in making the vaccine developed by AstraZeneca PLC and Oxford University.

Emergent BioSolutions says it has agreed with FDA not to manufacture new material at Baltimore facility

GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the second quarter of 2021, and financial outlook for full year 2021.

Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021

The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact.

Why Emergent BioSolutions Stock Fell Today

NEW YORK--(BUSINESS WIRE)-- #EmergentBioSolutions--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Emergent BioSolutions, Inc. (NYSE: EBS) on behalf of Emergent stockholders. Our investigation concerns whether Emergent has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On March 31, 2021, the New York Times published an article reporting on the accidental co

EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm

AUSTIN, Texas--(BUSINESS WIRE)--Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)

Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)

Big Lots

Cooper Companies

SPAR Group

Worthington Industries

According to the Peter Lynch Growth Screen, a Premium All-in-One Screener template, five stocks with high financial strength, good revenue growth and are trading below the Peter Lynch earnings line as of Tuesday are Big Lots Inc. (NYSE:BIG), The Cooper Companies Inc. (NYSE:COO), Emergent BioSolutions Inc. (NYSE:EBS), SPAR Group Inc. (NASDAQ:SGRP) and Worthington Industries Inc. (NYSE:WOR).

5 Peter Lynch Growth Stocks to Consider for 2nd Quarter

The move follows errors in the production of a batch of Johnson & Johnson's jab.

Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine

Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.

Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production

The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.

J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

Emergent BioSolutions Inc (NYSE: EBS) has announced topline data from Phase 3 trial, dubbed as INSIGHT-013 evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19.  The study was sponsored and supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to assess four immunoglobulin candidates' safety and efficacy plus standard of care versus placebo plus standard of care.

Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study; HHS Increases Task Order By $23M

Emergent BioSolutions Inc. said Monday it is on track with all commitments for COVID-19 vaccines and reaffirmed its financial guidance, after a production problem at its Baltimore plant last week ruined a batch of the vaccine developed by Johnson & Johnson . Emergent said it has received an additional $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health & Human Service, to purchase biologics manufacturing equipment that is specific to the J&J vaccine.

Emergent BioSolutions says on track with COVID vaccines, reaffirms guidance after J&J vaccine snafu

GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).

Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & John

AstraZeneca

Johnson & Johnson has been put in charge of COVID-19 vaccine production at a Baltimore plant where 15 million doses were ruined several weeks ago. What Happened: The U.S. Department of Health and Human Services put Johnson & Johnson (NYSE: JNJ) in charge of the Emergent BioSolutions Inc (NYSE: EBS) plant in Baltimore.

US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca

Emergent BioSolutions Inc. said Friday that its experimental COVID-19 treatment did not demonstrate a clinical benefit in a late-stage clinical trial. The study was testing Emergent's immunoglobulin candidate with the standard of care, which uses Gilead Sciences Inc.'s Veklury, in hospitalized patients with COVID-19 symptoms.

Emergent says experimental COVID-19 treatment failed in Phase 3 trial

GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) trial, also known as INSIGHT-013, sponsored and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), assessed the safety and efficacy of four immunoglobulin candidates plus standard of care versus placebo plus standard of care in hospitalized patients with COVID-19. Topline data from the ITAC trial demonstrated that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. There were no serious safety concerns identified.

Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

The company appears to have fumbled part of a very high-profile job for a big partner.

Why Emergent BioSolutions Crashed Today

Shares of Emergent BioSolutions tumbled 7.44% in premarket trading on Thursday after Johnson & Johnson said the biopharmaceutical manufacturing plant spoiled 15 million COVID-19 vaccine doses.  Emergent BioSolutions is a contract manufacturer that produces both the Johnson & Johnson and AstraZeneca coronavirus vaccines.

News for Emergent BioSolutions Stock (EBS)